Opthea To Present at Sequire Biotechnology Conference
30 janv. 2023 06h00 HE
|
Opthea Limited
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
12 déc. 2022 10h08 HE
|
Opthea Limited
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the FLORetina 2022 Congress
06 déc. 2022 06h00 HE
|
Opthea Limited
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at Jefferies London Healthcare Conference
10 nov. 2022 06h00 HE
|
Opthea Limited
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
24 oct. 2022 06h00 HE
|
Opthea Limited
Key appointment as Opthea progresses Phase 3 registrational trials of OPT-302 for wet AMD MELBOURNE, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical...
Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
30 août 2022 06h00 HE
|
Opthea Limited
Secured up to US$170m in non-dilutive financing Received commitments for well supported US$90m equity financing; closed first tranche for US$41.9 million Expanded management team and US operations...
Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
16 août 2022 07h46 HE
|
Opthea Limited
MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Successfully Closes Well Supported US$90 Million Equity Financing
14 août 2022 21h02 HE
|
Opthea Limited
MELBOURNE, Australia, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ: OPT) (Opthea), a clinical stage biopharmaceutical company developing novel therapies to treat highly...
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
14 août 2022 21h01 HE
|
Opthea Limited
Carlyle and its life sciences franchise Abingworth, working with their recently formed development company Launch Therapeutics (Launch Tx), to provide non-dilutive financing of up to US$170M,...
Opthea To Present at Upcoming Investor Conferences
11 mai 2022 08h00 HE
|
Opthea Limited
MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...